Last reviewed · How we verify
Activated T lymphocyte
Activated T lymphocyte is a T cell activator Biologic drug developed by GC Cell Corporation. It is currently in Phase 2 development for Treatment of various cancers. Also known as: Immuncell-LC.
Activated T lymphocytes are a type of immune cell that play a key role in the body's defense against infection and disease.
Activated T lymphocytes are a type of immune cell that play a key role in the body's defense against infection and disease. Used for Treatment of various cancers.
At a glance
| Generic name | Activated T lymphocyte |
|---|---|
| Also known as | Immuncell-LC |
| Sponsor | GC Cell Corporation |
| Drug class | T cell activator |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Activated T lymphocytes work by recognizing and binding to specific antigens, which triggers a cascade of immune responses to eliminate the pathogen. This process involves the activation of various immune cells, including T cells, B cells, and macrophages, which work together to eliminate the infection.
Approved indications
- Treatment of various cancers
Common side effects
- Immune-related adverse events
Key clinical trials
- Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma (PHASE1)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide (PHASE1)
- Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide (EARLY_PHASE1)
- Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas (PHASE1, PHASE2)
- A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 ) (PHASE1)
- Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
- Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Activated T lymphocyte CI brief — competitive landscape report
- Activated T lymphocyte updates RSS · CI watch RSS
- GC Cell Corporation portfolio CI
Frequently asked questions about Activated T lymphocyte
What is Activated T lymphocyte?
How does Activated T lymphocyte work?
What is Activated T lymphocyte used for?
Who makes Activated T lymphocyte?
Is Activated T lymphocyte also known as anything else?
What drug class is Activated T lymphocyte in?
What development phase is Activated T lymphocyte in?
What are the side effects of Activated T lymphocyte?
Related
- Drug class: All T cell activator drugs
- Manufacturer: GC Cell Corporation — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Treatment of various cancers
- Also known as: Immuncell-LC
- Compare: Activated T lymphocyte vs similar drugs
- Pricing: Activated T lymphocyte cost, discount & access